Syra Health Corp. Class A (SYRA)
OTHER OTC:SYRA
Top Page
Syra Health Corp. Class A
(OTC:SYRA)
Select Model
Select Model
Rating:53Neutral
Price Target:
$0.19
▲(112.22% Upside)
Action:ReiteratedDate:03/19/26
The score is driven primarily by improving financial trajectory (better margins, smaller losses, and reduced cash burn) but tempered by continued unprofitability and negative cash flow. Technicals are strong with price well above moving averages and positive MACD, though extremely overbought RSI/Stoch adds near-term risk. Valuation remains constrained by losses and lack of dividend support.
Positive Factors
Expanding gross margins and improving net margin
Material margin expansion shows the business is improving unit economics via pricing, cost control, or mix shift. Sustained higher gross margins reduce the revenue needed to cover fixed costs, materially improving the company's structural path toward operating profitability over the coming months.
Negative Factors
Persistent unprofitability
Despite margin improvement, recurring net losses mean the firm still depends on improvement to reach durable profitability. Continued losses erode equity and require either sustained operational improvement or external funding to maintain program delivery and client support over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Expanding gross margins and improving net margin
Material margin expansion shows the business is improving unit economics via pricing, cost control, or mix shift. Sustained higher gross margins reduce the revenue needed to cover fixed costs, materially improving the company's structural path toward operating profitability over the coming months.
Read all positive factors
Syra Health Corp. Class A (SYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.03M
Dividend YieldN/A
Average Volume (3M)9.76K
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue Growth-3.14%
EPS Growth81.98%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.01
Shares Outstanding11,339,169
10 Day Avg. Volume11,249
30 Day Avg. Volume9,759
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.49
Price to Sales (P/S)0.14
P/FCF Ratio-2.28
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue0.03
Enterprise Value/Gross Profit0.11
Enterprise Value/Ebitda-0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Syra Health Corp. Class A Business Overview & Revenue Model
Company Description
Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, i...
How the Company Makes Money
Syra Health makes money primarily by providing services under contracts and engagements, with revenue generally earned as it delivers project work and ongoing program support. Key revenue streams include: (1) government and public-sector contracti...
Syra Health Corp. Class A Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments such as revenue growth in the Population Health unit and improved operational efficiencies, alongside challenges like NASDAQ delisting, federal contract delays, and a decline in Healthcare Workforce revenue. The balance of achievements and setbacks suggests a cautious outlook.Positive Updates
Revenue Growth
Total revenue for Q1 2025 was $1.9 million, reflecting a 6% annual growth compared to Q1 2024. This growth was primarily driven by strong performance in the Population Health business unit.
Negative Updates
Delisting from NASDAQ
The company announced a strategic decision to voluntarily delist from the NASDAQ capital market to reduce costs and strengthen core fundamentals.
Read all updates
Q1-2025 Updates
Positive
Negative
Revenue Growth
Total revenue for Q1 2025 was $1.9 million, reflecting a 6% annual growth compared to Q1 2024. This growth was primarily driven by strong performance in the Population Health business unit.
Read all positive updates
Company Guidance
During the first quarter of 2025, Syra Health reported positive financial metrics, with total revenue reaching $1.9 million, reflecting a 6% annual growth compared to the same period in 2024. The company achieved a substantial gross margin expansion of 14.6 percentage points, reaching 31.7%, driven by the strong performance of its Population Health business unit, which contributed 65% of total revenue. This unit experienced a 261% year-over-year revenue increase, supported by new contracts and extensions. Despite a 39% reduction in operating expenses, Syra reported a net loss of $472,000, a significant improvement from the $1.4 million loss recorded in the first quarter of 2024. The company also highlighted a strategic shift towards higher-margin, recurring revenue streams and announced the voluntary delisting from NASDAQ to focus on core fundamentals. However, ongoing federal-level changes pose potential challenges, affecting revenue visibility and leading to the withdrawal of previous full-year guidance.Syra Health Corp. Class A Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.23M | 7.98M | 5.52M | 5.62M | 1.41M |
| Gross Profit | 2.49M | 1.65M | 1.41M | 1.06M | 430.35K |
| EBITDA | -883.86K | -3.68M | -2.84M | -2.07M | -3.07K |
| Net Income | -896.33K | -3.76M | -2.94M | -2.12M | -3.28K |
Balance Sheet | |||||
| Total Assets | 2.77M | 3.68M | 4.92M | 2.32M | 536.89K |
| Cash, Cash Equivalents and Short-Term Investments | 1.61M | 2.40M | 3.28M | 3.34K | 100.01K |
| Total Debt | 143.79K | 452.08K | 248.10K | 934.84K | 342.86K |
| Total Liabilities | 674.74K | 800.76K | 910.07K | 1.61M | 544.04K |
| Stockholders Equity | 2.10M | 2.88M | 4.01M | 710.10K | -7.15K |
Cash Flow | |||||
| Free Cash Flow | -447.85K | -2.94M | -2.77M | -2.37M | -94.49K |
| Operating Cash Flow | -447.75K | -2.93M | -2.76M | -2.24M | -88.20K |
| Investing Cash Flow | -107.00 | -11.11K | -15.25K | -121.26K | -6.29K |
| Financing Cash Flow | -332.82K | 2.06M | 6.05M | 2.27M | 191.50K |
Syra Health Corp. Class A Technical Analysis
Positive
0.09
Price Trends
0.10
Positive
0.09
Positive
0.09
Positive
Market Momentum
0.02
Negative
78.10
Negative
80.51
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Positive. The current price of 0.09 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.10, and above the 200-day MA of 0.09, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 78.10 is Negative, neither overbought nor oversold. The STOCH value of 80.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRA.
Syra Health Corp. Class A Risk Analysis
Syra Health Corp. Class A disclosed 49 risk factors in its most recent earnings report. Syra Health Corp. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Syra Health Corp. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $2.03M | -1.14 | -39.06% | ― | -3.14% | 81.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $12.48M | -271.02 | -8.75% | ― | 17.84% | -156.13% | |
44 Neutral | $16.30M | -0.11 | ― | ― | -22.38% | 56.66% | |
43 Neutral | $23.92M | -13.22 | 15.27% | 11.14% | -0.29% | 94.56% | |
43 Neutral | $22.41M | -0.23 | -257.39% | ― | -2.15% | -6.72% |
* Healthcare Sector Average
SYRA
Syra Health Corp. Class A
0.17
-0.13
-43.52%
AMS
American Shared Hospital Services
1.90
-0.88
-31.53%
CCM
Concord Medical Services
3.76
-0.53
-12.27%
CCEL
Cryo-Cell International
2.97
-3.28
-52.44%
PIII
P3 Health Partners
3.11
-5.79
-65.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.